Nothing Special   »   [go: up one dir, main page]

DK3678648T3 - Fremgangsmåder til anvendelse af dipivefrin - Google Patents

Fremgangsmåder til anvendelse af dipivefrin Download PDF

Info

Publication number
DK3678648T3
DK3678648T3 DK18779156.1T DK18779156T DK3678648T3 DK 3678648 T3 DK3678648 T3 DK 3678648T3 DK 18779156 T DK18779156 T DK 18779156T DK 3678648 T3 DK3678648 T3 DK 3678648T3
Authority
DK
Denmark
Prior art keywords
dipivefrin
methods
Prior art date
Application number
DK18779156.1T
Other languages
English (en)
Inventor
Mingbao Zhang
Original Assignee
Insignis Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Insignis Therapeutics Inc filed Critical Insignis Therapeutics Inc
Application granted granted Critical
Publication of DK3678648T3 publication Critical patent/DK3678648T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/16Central respiratory analeptics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Virology (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Mobile Radio Communication Systems (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK18779156.1T 2017-09-08 2018-09-10 Fremgangsmåder til anvendelse af dipivefrin DK3678648T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762555854P 2017-09-08 2017-09-08
PCT/US2018/050223 WO2019051387A1 (en) 2017-09-08 2018-09-10 METHODS OF USING DIPIVECHINE

Publications (1)

Publication Number Publication Date
DK3678648T3 true DK3678648T3 (da) 2023-09-11

Family

ID=63686134

Family Applications (1)

Application Number Title Priority Date Filing Date
DK18779156.1T DK3678648T3 (da) 2017-09-08 2018-09-10 Fremgangsmåder til anvendelse af dipivefrin

Country Status (14)

Country Link
US (2) US11213496B2 (da)
EP (1) EP3678648B1 (da)
JP (2) JP6837700B2 (da)
KR (1) KR102182559B1 (da)
CN (1) CN111565716B (da)
AU (1) AU2018330329B2 (da)
BR (1) BR112020004586A2 (da)
CA (1) CA3075271C (da)
DK (1) DK3678648T3 (da)
EA (1) EA202090637A1 (da)
ES (1) ES2954361T3 (da)
IL (1) IL272851B (da)
SG (1) SG11202001397VA (da)
WO (1) WO2019051387A1 (da)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111565716B (zh) 2017-09-08 2023-06-09 因斯格尼斯疗法有限公司 使用地匹福林的方法
US11213484B2 (en) 2019-03-01 2022-01-04 Insignis Therapeutics, Inc. Dipivefrin orally disintegrating tablet formulations
CN111803635B (zh) * 2020-06-17 2023-03-14 中国医学科学院基础医学研究所 小分子抑制剂在治疗呼吸道病毒性肺炎上的应用
WO2023076477A2 (en) 2021-10-27 2023-05-04 Insignis Therapeutics, Inc. Orally disintegrating tablet for epinephrine prodrug formulations

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3904671A (en) * 1969-04-01 1975-09-09 Sterling Drug Inc Esters of 3-(hydroxy or hydroxymethyl)-4-hydroxyphenyl aminomethyl ketones
NL7213759A (da) * 1971-10-19 1973-04-25
US3839584A (en) 1972-08-31 1974-10-01 Interx Research Corp Pharmaceutical compositions containing a novel ester of ((methylamino)methyl)benzyl alcohol and methods of using same
US3809714A (en) * 1972-08-31 1974-05-07 Interx Research Corp Novel ester of ((methylamino)methyl) benzyl alcohol
US3868461A (en) 1972-11-22 1975-02-25 Interx Research Corp Ester of 3,4-dihydroxy-alpha (isopropylamino) methyl benzyl alcohol, composition and anti-asthma use thereof
US4035405A (en) 1976-07-09 1977-07-12 Interx Research Corporation Novel synthesis for preparing the hydrochloride salt of selected catecholamine derivatives
US4180586A (en) 1977-01-10 1979-12-25 Interx Research Corporation 3,4-Dipivalyl-α-[methylamino)methyl]benzyl alcohol as an adjunct in the treatment of circulatory shock
US4094983A (en) 1977-01-17 1978-06-13 Interx Research Corporation Method for reducing intraocular pressure in warm-blooded animals
US4145441A (en) 1977-11-04 1979-03-20 Interx Research Corporation Sympathomimetic amines exhibiting anti-hemorrhoidal activity
FR2561916B1 (fr) 1984-03-30 1987-12-11 Lafon Labor Forme galenique pour administration orale et son procede de preparation par lyophilisation d'une emission huile dans eau
US5622716A (en) 1987-02-20 1997-04-22 Farmarc Nederland B.V. Process for preparing a retard product containing diltiazem for a single daily administration
CA2125579C (en) 1991-12-17 2005-06-21 Richard C. Fuisz Ulcer prevention treatment composition and method
US5654003A (en) 1992-03-05 1997-08-05 Fuisz Technologies Ltd. Process and apparatus for making tablets and tablets made therefrom
US5622719A (en) 1993-09-10 1997-04-22 Fuisz Technologies Ltd. Process and apparatus for making rapidly dissolving dosage units and product therefrom
US5895664A (en) 1993-09-10 1999-04-20 Fuisz Technologies Ltd. Process for forming quickly dispersing comestible unit and product therefrom
US5567439A (en) 1994-06-14 1996-10-22 Fuisz Technologies Ltd. Delivery of controlled-release systems(s)
US5925682A (en) 1995-11-20 1999-07-20 Immunotech Inc. Epinephrine as inhibitor of cancerous tumors
US6596298B2 (en) 1998-09-25 2003-07-22 Warner-Lambert Company Fast dissolving orally comsumable films
US7067116B1 (en) 2000-03-23 2006-06-27 Warner-Lambert Company Llc Fast dissolving orally consumable solid film containing a taste masking agent and pharmaceutically active agent at weight ratio of 1:3 to 3:1
JP4994570B2 (ja) * 2001-07-04 2012-08-08 サン・ファーマ・アドバンスド・リサーチ・カンパニー・リミテッド 胃保持制御ドラッグデリバリーシステム
WO2003041740A1 (fr) 2001-11-16 2003-05-22 Ajinomoto Co., Inc. Agent de necrose tumorale
JP2004231557A (ja) 2003-01-30 2004-08-19 Katsuyoshi Hori エピネフリン含有抗腫瘍剤
CA2523372A1 (en) 2003-05-02 2004-11-11 Warner-Lambert Company Llc Fast dissolving orally consumable films containing a modified starch for improved heat and moisture resistance
JP2006193440A (ja) * 2005-01-12 2006-07-27 Medorekkusu:Kk β2刺激剤含有製剤
WO2007028247A1 (en) 2005-09-09 2007-03-15 University Of Manitoba Fast-disintegrating epinephrine tablets for buccal or sublingual administration
US20070202163A1 (en) * 2005-09-09 2007-08-30 Mutasem Rawas-Qalaji Fast-disintegrating epinephrine tablets for buccal or sublingual administration
US20150164827A1 (en) * 2005-09-09 2015-06-18 Nova Southeastern University Epinephrine nanoparticles, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinephrine
US9877921B2 (en) 2005-09-09 2018-01-30 Nova Southeastern University Epinephrine nanoparticles, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinephrine
CA2642761A1 (en) 2006-02-23 2007-08-30 Iomedix Sleep International Srl Compositions and methods for the induction and maintenance of quality sleep
US20070293582A1 (en) * 2006-06-05 2007-12-20 Malcolm Hill Epinephrine dosing regimens comprising buccal, lingual or sublingual and injectable dosage forms
CN101896204B (zh) 2007-11-16 2015-05-20 爱力根有限公司 用于治疗紫癜的组合物及方法
DE102008007198A1 (de) 2008-02-01 2009-08-13 Infectopharm Arzneimittel Und Consilium Gmbh Oral oder nasal applizierbare Epinephrin- haltige Zubereitungen mit verbesserten Eigenschaften
US20120322884A1 (en) * 2010-03-01 2012-12-20 University Of Manitoba Epinephrine nanoparticles, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinephrine
CA2853084C (en) 2011-10-21 2022-04-26 Nova Southeastern University Epinephrine nanoparticles, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinephrine
US9789071B2 (en) 2012-06-27 2017-10-17 G2B Pharma, Inc. Intranasal formulation of epinephrine for the treatment of anaphylaxis
EP3041461A4 (en) 2013-09-03 2017-05-03 G2B Pharma Inc. Intranasal formulation for the treatment of cardiopulmonary resuscitation (cpr), cardiac life support (cls), anaphylaxis and/or anaphylactoid reactions
GB201419257D0 (en) * 2014-10-29 2014-12-10 Jagotec Ag Pharmaceutical compositions
TWI746449B (zh) 2015-07-20 2021-11-21 美商Ai治療公司 使用阿吡莫德治療癌症之方法
US20180297966A1 (en) 2015-10-17 2018-10-18 Innovative Anesthetics, Llc Compounds, compositions, and methods of making and using the same
CN106109459A (zh) 2016-06-22 2016-11-16 丁俣汀 盐酸地匹福林的药物组合物及其在生物医药中的应用
CN110418639B (zh) 2016-11-13 2023-06-02 艾奥诺医药有限公司 肾上腺素前药的舌下或口含给药制剂
CN111565716B (zh) 2017-09-08 2023-06-09 因斯格尼斯疗法有限公司 使用地匹福林的方法
US11213484B2 (en) 2019-03-01 2022-01-04 Insignis Therapeutics, Inc. Dipivefrin orally disintegrating tablet formulations

Also Published As

Publication number Publication date
EA202090637A1 (ru) 2020-06-29
AU2018330329A1 (en) 2020-03-12
CN111565716B (zh) 2023-06-09
CA3075271C (en) 2021-10-12
EP3678648B1 (en) 2023-07-26
BR112020004586A2 (pt) 2020-09-08
WO2019051387A1 (en) 2019-03-14
ES2954361T3 (es) 2023-11-21
IL272851A (en) 2020-04-30
US20220193010A1 (en) 2022-06-23
CA3075271A1 (en) 2019-03-14
JP2021063135A (ja) 2021-04-22
US11213496B2 (en) 2022-01-04
KR20200040898A (ko) 2020-04-20
JP2020528928A (ja) 2020-10-01
EP3678648A1 (en) 2020-07-15
US20190076378A1 (en) 2019-03-14
CN111565716A (zh) 2020-08-21
KR102182559B1 (ko) 2020-11-24
JP6837700B2 (ja) 2021-03-03
IL272851B (en) 2021-12-01
AU2018330329B2 (en) 2020-12-03
SG11202001397VA (en) 2020-03-30

Similar Documents

Publication Publication Date Title
DK3512850T3 (da) Inhibitorer af menin-mll-interaktionen
DK3468966T3 (da) Inhibitorer af menin-mll-interaktionen
DK3315610T3 (da) Fremgangsmåde til fremstilling af fucosylerede oligosaccharider
DK3282836T3 (da) Fremgangsmåde til opdræt af insekter
DK3292134T3 (da) Metode til dyrkning af akkermansia
DK3668851T3 (da) Fremgangsmåde til fremstilling af thiocarbonater
DK3192902T3 (da) Fremgangsmåde til fremstilling af graphenholdige viscosefibre
DK3325443T3 (da) Fremgangsmåde til fremstilling af pridopidin
DK3137169T3 (da) Hæmmere af lysin-specifik demethylase-1
DK3185868T3 (da) Hidtil ukendte ULK1-inhibitorer og fremgangsmåder til anvendelse af samme
DK3096741T3 (da) Fremgangsmåde til fremstillingen af hybridosomer
DK3554240T3 (da) Kombinationer af aktive forbindelser
DK3317400T3 (da) Fremgangsmåde til kryokonservering af tumorinfiltrerende lymfocytter
DK3160956T3 (da) Inhibitorer af lysin-specifik demethylase-1
DK3484469T3 (da) Sammensætninger og fremgangsmåder til potentiering af antimikrober
DK3174858T3 (da) Fremgangsmåde til fremstilling af pyrazoler
DK3511319T3 (da) Hæmmere af lysinspecifik demethylase-1
DK3402773T3 (da) Fremgangsmåde til fremstilling af methanol
DK3473621T3 (da) Fremgangsmåde til fremstilling af diphenylmethan-derivat
DK3458100T3 (da) Selektiv reduktion af cystein-manipulerede antistoffer
DK3515990T3 (da) Fremgangsmåde til fremstilling af lignocellulosematerialer
DK3280408T3 (da) Fremgangsmåde til fremstilling af dicycloplatin
DK3191498T3 (da) Fremgangsmåde til fremstilling af 2'-o-fucosyllactose
DK3612845T3 (da) Fremgangsmåde til kontaktløs bestemmelse af flowparametre
DK3538960T3 (da) Sekvens styring af programmoduler